Mangalam Drugs And Organics Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Only consolidated filings are available for this company — standalone cannot be selected.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 169 Cr | 266 Cr | 369 Cr | 77 Cr | 156 Cr | 89 Cr | 73 Cr | 57 Cr | 50 Cr | 58 Cr | 67 Cr |
| Operating expenses (approx.) | 170 Cr | 261 Cr | 351 Cr | 68 Cr | 139 Cr | 80 Cr | 63 Cr | 62 Cr | 52 Cr | 60 Cr | 73 Cr |
| EBITDA | -1 Cr | 6 Cr | 17 Cr | 8 Cr | 17 Cr | 9 Cr | 10 Cr | -4 Cr | -3 Cr | -1 Cr | -6 Cr |
| OPM % | -0.7% | 2.2% | 4.7% | 10.7% | 10.9% | 10.0% | 14.2% | -7.8% | -5.7% | -2.3% | -8.2% |
| Other income | 0.07 Cr | 0.05 Cr | 0.10 Cr | 0.02 Cr | 0.16 Cr | 0.14 Cr | 0.21 Cr | 0.0004 Cr | 0.03 Cr | 0.11 Cr | 0.09 Cr |
| Interest | 7 Cr | 10 Cr | 14 Cr | 4 Cr | 7 Cr | 3 Cr | 4 Cr | 4 Cr | 5 Cr | 4 Cr | 3 Cr |
| Depreciation | 7 Cr | 11 Cr | 15 Cr | 4 Cr | 8 Cr | 4 Cr | 5 Cr | 4 Cr | 5 Cr | 4 Cr | 5 Cr |
| Profit before tax | -15 Cr | -15 Cr | -11 Cr | 0.58 Cr | 2 Cr | 1 Cr | 2 Cr | -13 Cr | -12 Cr | -10 Cr | -13 Cr |
| Tax % | 12.9% | 16.0% | 18.1% | -359.2% | -201.2% | 5.9% | 96.4% | -6.2% | 41.1% | -0.0% | -1.1% |
| Net profit | -13 Cr | -13 Cr | -9 Cr | 3 Cr | 5 Cr | 1 Cr | 0.06 Cr | -14 Cr | -7 Cr | -10 Cr | -13 Cr |
| EPS (₹) | ₹-8.28 | ₹-7.96 | ₹-5.73 | ₹1.70 | ₹3.40 | ₹0.81 | ₹0.04 | ₹-8.72 | ₹-4.64 | ₹-6.21 | ₹-8.48 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 318 Cr | 232 Cr | Sign in for TTM |
| Operating expenses (approx.) | 282 Cr | 246 Cr | Sign in for TTM |
| EBITDA | 36 Cr | -14 Cr | Sign in for TTM |
| OPM % | 11.4% | -6.1% | Sign in for TTM |
| Other income | 0.50 Cr | 0.76 Cr | Sign in for TTM |
| Interest | 15 Cr | 16 Cr | Sign in for TTM |
| Depreciation | 17 Cr | 18 Cr | Sign in for TTM |
| Profit before tax | 5 Cr | -49 Cr | Sign in for TTM |
| Tax % | -40.4% | 8.6% | Sign in for TTM |
| Net profit | 7 Cr | -44 Cr | Sign in for TTM |
| EPS (₹) | ₹4.25 | ₹-28.05 | Sign in for TTM |
| Dividend payout % | 0.0% | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 16 Cr | 16 Cr |
| Reserves | 126 Cr | 87 Cr |
| Borrowings | 72 Cr | 97 Cr |
| Other liabilities | 146 Cr | 115 Cr |
| Total liabilities | 366 Cr | 315 Cr |
| Fixed assets (net) | 134 Cr | 116 Cr |
| CWIP | 0.0000 Cr | 0.0000 Cr |
| Investments | 0.0044 Cr | 0.0044 Cr |
| Other assets | 200 Cr | 156 Cr |
| Total assets | 366 Cr | 315 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operating activity | 43 Cr | 4 Cr |
| Cash from investing | -19 Cr | -12 Cr |
| Cash from financing | -22 Cr | 6 Cr |
| Net cash flow | 1 Cr | -2 Cr |
| Free cash flow (OCF − Capex) | 22 Cr | -8 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | 8.9% | -16.2% |
| ROE % | 0.0% | 0.0% |
| Debtor days | — | — |
| Inventory days | 296 | 300 |
| Days payable | — | — |
| Cash conversion cycle | 296 | 300 |
| Debt / equity | 0.48 | 0.94 |
| Current ratio | 1.04 | 0.79 |
| Net debt / EBITDA | 1.91 | — |
Compare with peers
Loading peers…